Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
株式のランク #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
株価
$0.30780727
時価総額
$94.19M
変化(1日)
-0.19%
変化(1年)
-34.73%
FR
取引 Sensorion SA (ALSEN)

カテゴリー

Sensorion SA(ALSEN)の営業利益率
July 2026 時点の営業利益率 TTM: -1,571.42%
Sensorion SA の最新の財務報告と株価によると、現在の営業利益率(TTM)は -1,571.42% です。2023 年末時点では -391.55% でした。
Sensorion SA の営業利益率の履歴(2011 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -1,571.42% 268.11%
2024 -426.89% 9.03%
2023 -391.55% -31.27%
2022 -569.66% 25.52%
2021 -453.84% -5.45%
2020 -480.00% -11.46%
2019 -542.11% -1.74%
2018 -551.69% 11.09%
2017 -496.61% -99.05%
2016 -52,039.05% 1,440.05%
2015 -3,379.05% 173.23%
2014 -1,236.72% 195.80%
2013 -418.10% -0.43%
2012 -419.89% -99.99%
2011 -3,064,766.67% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
45.30% -100.03%
DK
38.97% -100.02%
US
24.32% -100.02%
US
25.32% -100.02%
BE
25.64% -100.02%
NL
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。